StockNews.AISignal intelligence
Moderna, Inc. · NASDAQ · Healthcare
Browse public MRNA signals with their source context and measured market impact. Open any signal for its permanent analysis page.
Moderna reported Q3 2026 EPS of $0.38 and net income of $162M on $1.31B revenue, and raised FY2026 growth guidance to 15%–25% while boosting year-end cash guidance to $8.1–8.3B and trimming R&D guidance.
View signal analysisModerna faces near-term stock-pressure after a valuation-driven downgrade following a 545% YTD rally. INTerpath-001 melanoma data with pembrolizumab could influence rollout if results mature, while investors now weigh multi-tumor potential versus Merck’s Keytruda. With a $79.4B market cap and upcoming 2027 Phase 2 readouts, sentiment hinges on pipeline breadth and data clarity.
View signal analysisModerna and Merck reported a positive Phase 3 melanoma trial, with a 42% relative reduction in recurrence or death versus Keytruda, though data leaks led to a sharp stock drop. Regulatory discussions could begin within months, and patient access may start next year if approved. The result validates a personalized mRNA approach but questions remain about long-term durability and broader applicability.
View signal analysisAn alleged leak of an ESMO 2026 abstract suggests intismeran autogene plus Keytruda yielded a 42% reduction in recurrence or death (HR 0.58) in Phase 3, but results are unverified. This compares with a 49% reduction in Phase 2b, prompting questions whether the vaccine adds value beyond existing immunotherapy.
View signal analysisModerna and Merck's personalized cancer vaccine intismeran autogene, paired with Keytruda, reduced recurrence or death by 42% in certain melanoma patients in a late-stage trial. Shares fell up to 25% on a pre-release leak, but subsequent full data aligned with expectations. The upcoming ESMO presentation could trigger a sentiment and valuation re-rating if results hold.
View signal analysisModerna stock trades higher ahead of detailed Phase 3 melanoma results from the INTerpath-001 trial, where intismeran autogene plus Keytruda showed improvements in recurrence-free and distant metastasis-free survival. A target upgrade to $220 and Nasdaq-100 inclusion add near-term upside catalysts, though overall survival data has not been disclosed yet. Jefferies projects melanoma sales above $3 billion, supporting upside if data readouts confirm expectations.
View signal analysis